Sildenafil citrate for the treatment of pulmonary hypertension

Drugs of Today

Volumn 42, Issue 12, 2006, Pages 771-784

  Hrometz, Sandra L ^a   Shields, Kelly M ^a  

^a OHIO NORTHERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; ANTICOAGULANT AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; COCAINE; DIGOXIN; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; ILOPROST; METHAMPHETAMINE; NIFEDIPINE; NITRIC OXIDE; OXYGEN; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROTEINASE INHIBITOR; SILDENAFIL; TADALAFIL; TRYPTOPHAN; UNIPROST; VARDENAFIL; WARFARIN;

BACKACHE; BLOOD PRESSURE MEASUREMENT; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STORAGE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FLUSHING; GASTROINTESTINAL SYMPTOM; HAND PARESTHESIA; HEADACHE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPOTENSION; LEG EDEMA; LIVER TOXICITY; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; MYALGIA; OPTIMAL DRUG DOSE; OXYGEN THERAPY; PARESTHESIA; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SMOOTH MUSCLE TONE; TREATMENT DURATION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION, PULMONARY; PEDIATRICS; PIPERAZINES; PROSTAGLANDINS I; PURINES; RANDOMIZED CONTROLLED TRIALS; SULFONES; VASODILATOR AGENTS;

EID: 33846945409     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2006.42.12.1032057     Document Type: Review

References (85)

1. Abenhaim, L., Moride, Y., Benot, F. et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996, 335: 609-16.
2. Rubin, L.J., Barst, R.J., Kaiser, L.R. et al. Primary pulmonary hypertension. Chest 1993, 104: 236-50.
3. Rubin, L.J. Executive summary: Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004, 126 (Suppl. 1): 1S-19.
4. National Heart, Lung and Blood Institute Disease Index. http://www.nhlbi.nih.gov/health/dci/Diseases/pah/pah_what.html. Cited August 17, 2006.
5. Simonneau, G., Galie, N., Rubin, L.J. et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004, 43 (Suppl. 12): 5S-12.
6. D'Alonzo, G.E., Barst, R.J., Ayres, S.M. et al. Survival in patients with primary pulmonary hypertension: Results from a national prospective registry. Ann Intern Med 1991, 115: 343-9.
7. McLaughlin, V.V., Presberg, K.W., Doyl, R.L. et al. Prognosis of pulmonary arterial hypertension/ACCP evidence-based clinical practice guidelines. Chest 2004, 126: 78S-92.
8. Rich, S., Kaufmann, E., Levy, P.S. et al The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992, 327: 76-81.
9. Rubin, L.J., Mendoza, J., Hood, M. et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): Results of a randomized trial. Ann Intern Med 1994, 121: 485-91.
10. Milnor, W.R. Cardiovascular Physiology, 1st edition. Oxford University Press Inc., New York, 1990.
11. Levitsky, M.G. Pulmonary Physiology, 6th edition. McGraw-Hill, New York, 2003.
12. Campbell, J.H., Campbell, G.R. Endothelial cell influences on vascular smooth muscle phenotype. Annu Rev Physiol 1985, 48: 295-306
13. Tanabe, T., Volker, U. Prostacyclin and thromboxane syntheses. J Lipid Medial Cell Signal 1995, 12: 243-55.
14. 2. J Appl Physiol 1980, 49: 107-12.
15. Radomski, M.W., Palmer, R.M.J., Moncada, S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987, 92: 181-7
16. Svensson, J., Hamberg, M., Samuelsson, B. On the formation and effects of thromboxane A2 in human platelets. Acta Physiologica Scandinavica 1976, 98: 285-94.
17. Granstrom, E., Diczfalusy, U., Hamberg, M. et al. Thromboxane A2: Biosynthesis and effects on platelets. Adv Prostaglandin Thromboxane Leukot Res 1982, 10: 15-58.
18. Palmer, R.M., Ferrige, A.G., Moncada, S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987, 327: 524-6.
19. Loscalzo, J., Welch, G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 1995, 38: 87-104.
20. Buechler, W.A., Ivanova, K., Wolfram, G. et al. Soluble guanylyl cyclase and platelet function. Ann NY Acad Sci 1994, 714: 151-7.
21. Radomski, M.W., Moncada, S. The biological and pharmacological role of nitric oxide in platelet function. Adv Exp Med Biol 1993, 344: 251-64.
22. Azuma, H., Ishikawa, M., Sekizaki, S. Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol 1986, 88: 411-5.
23. Furlong, B., Henderson, A.H., Lewis, M.J. et al. Endothelium-derived relaxing factor inhibits in vitro platelet aggregation. Br J Pharmacol 1987, 90: 687-92.
24. Cooke, J.P., Dzau, V.J. Nitric oxide synthase: Role in the genesis of vascular disease. Ann Rev Med 1997, 48: 489-509.
25. Rudic, R.D., Shesely, E.G., Maeda, N. et al. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest 1998, 101: 731-6.
26. Palmer, R.M.J., Ashton, D.S., Moncada, S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (Lond) 1988, 333: 664-6.
27. Palmer. R.M.J., Rees, D.D., Ashton, D.S. et al. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun 1988, 153: 1251-6.
28. Palmer, R.M.J., Moncada, S. A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem Biophys Res Commun 1989, 158: 48-52.
29. Arnold, W.P., Mittal, C.K., Katsuki, S. et al. Nitric oxide activates guanylate cyclase and increases 3′-5′-monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA 1977, 74: 3203-7.
30. Moncada, S., Higgs, A. The L-arginine nitric oxide pathway. N Engl J Med 1993, 329: 2002-12.
31. Beavo, J.A., Reifsnyder, D.H. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci 1990, 11: 150-5.
32. Ahn, H., Foster, M., Cable, M. et al. Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and nonvascular tissues. Adv Exp Med Biol 1991, 308: 191-7.
33. Benigni, A., Remuzzi, G. Endothelin antagonists. Lancet 1999, 353: 133-9.
34. Rich, S., Dantzker, D.R., Ayres, S.M. et al, Primary pulmonary hypertension: A national prospective study. Ann Intern Med 1987, 107: 216-23.
35. Deng, Z., Morse, J.H., Slager, S.L. et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000, 67: 737-44.
36. Lane, K.B., Machado R.D., Pauciulo, M.W. et al. Heterozygous germline mutations in BM-PR2, encoding a TGF-beta receptor, causes familial primary pulmonary hypertension. The International PPH Consorium. Nat Genet 2000, 26: 81-4.
37. Thomson, J.R., Machado, R.D., Pauciulo, M.W. et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family. J Med Genet 2000, 37: 741-5.
38. Jeffery, T.K., Morrell, N.W. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 2002, 45: 173-202.
39. Archer, S., Rich, S. Primary pulmonary hypertension: A vascular biology and translational research "Work in Progress". Circ 2000, 102: 781-91.
40. Rubin, L.J. Primary pulmonary hypertension. N Engl J Med 1997, 336: 111-7.
41. Tuder, R.M., Groves, B., Badesch, D.B. et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994, 144: 275-85.
42. Cool, C.D., Groshong, S.D., Oakey, J., Voelkel, N.F. Pulmonary hypertension: Cellular and molecular mechanisms. Chest 2005, 128: 565S-71.
43. Weir, E.K., Archer, S.L. The mechanism of acute hypoxic pulmonary vasoconstriction: The tale of two channels. FASEB J 1995, 9: 183-9.
44. Post, J., Hume, J., Archer, S. et al. Direct role for potassium channel inhibition in hypoxic pulmonary vasoconstriction. Am J Physiol 1992, 262: C882-90.
45. Archer, S.L., Souil, E., Dinh-Xuan, A.T. et al. Molecular identification of the role of voltage-gated K+ channels, Kv1.5 and KV2.1, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes. J Clin Invest 1998, 101: 2319-30.
46. Yuan, X.J., Wang, J., Juhaszova, M. et al. Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet 1998, 351: 726-7.
47. Humbert, M., Morrell, N.W., Archer, S.L. et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43 (Suppl. 12): 13S-24.
48. Farber, H.W., Loscalzo, J. Pulmonary arterial hypertension. N Engl J Med 2004, 351: 1655-65.
49. Giaid, A., Yanagisawa, M., Langleben, D. et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993, 328: 1732-9.
50. Giaid, A., Saleh, D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995, 333: 214-21.
51. Ghofrani, H.A., Pepke-Zaba, J., Barbera, J.A. et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43 (Suppl. 12): 68S-72.
52. Hanson, K.A., Burns, F., Rybalkin, S.D. et al. Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. Am J Respir Crit Care Med 1998, 158: 279-88.
53. Tuder, R.M., Cool, C.D., Geraci, M.W. et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999, 159: 1925-32.
54. Christman, B.W., McPherson, C.D., Newman, J.H. et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992, 327: 70-5.
55. Galie, N., Grigioni, F., Bacchi-Raggiani, L. et al. Relation of endothelin-1 to survival in patients with primary pulmonary hypertension. Eur J Clin Invest 1996, 26: 273.
56. Yamane, K. Endothelin and collagen vascular disease: A review with special reference to Raynaud's phenomenon and systemic sclerosis. Intern Med 1994, 33: 579-82.
57. Kim, H., Yung, G.L., Marsh, J.J. et al. Endothelin mediates pulmonary vascular remodeling in a canine model of chronic embolic pulmonary hypertension. Eur Respir J 2000, 15: 640-8.
58. Badesch, D.B., Abman, S.H., Ahearn, G.S. et al. Medical therapy for pulmonary arterial hypertension. Chest 2004, 126: 35S-62.
59. Galie, N., Toricki, A., Barst, R. et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004, 25: 2243-78.
60. Ghofrani, H.A., Wiedemann, R., Rose, F. et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002, 136: 515-22.
61. Wilkins, M.R., Paul, G.A., Strange, J.W. et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SER-APH) study. Am J Respir Crit Care Med 2005, 171: 1292-7.
62. McEvoy, G.K. (Ed.). AHFS Drug Information 2006. American Society of Health-System Pharmacists, Inc., Bethesda, 2006.
63. Corbin, J.D., Fancis, S.H. Cyclic GMP phosphodiesterase-5: Target of sildenafil. J Biol Chem 1999, 274: 13729-32.
64. Ricciardi, M.J., Knight, B.P., Martinez, F.J. et al. Inhaled nitric oxide in primary pulmonary hypertension: A safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol 1998, 32: 1068-73.
65. Hasuda, T., Satoh, T., Shimouchi, A. et al. Improvement in exercise capacity with nitric oxide inhalation in patients with precapillary pulmonary hypertension. Circulation 2000, 101: 2066-70.
66. Clark, W.R., Uezono, S., Chambers, A. et al. The type III phosphodiesterase inhibitor milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance. Pulm Pharmacol 1994, 7: 81-9.
67. Thusu, K.G., Morin, F.C. 3rd, Russell, J.A. et al. The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide. Am J Respir Crit Care Med 1995, 152: 1605-10.
68. Ziegler, J.W., Ivy, D.D., Wiggins, J.W. et al. Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. Am J Respir Crit Care Med 1998, 158: 1388-95.
69. Channick, R.N., Newhart, J.W., Johnson, F.W. et al. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: An ambulatory delivery system and initial clinical tests. Chest 1996, 109: 1545-9.
70. Pepke-Zaba, J., Higenbottam, T.W., Dinh-Xuan, A.T. et al Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet 1991, 338: 1173-4.
71. Tantini, B., Manes, A., Fiumana, E. Anti-proliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 2005, 100: 131-8.
72. Zhao, L., Mason, N.A., Morrell, N.W. et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001, 104: 424-8.
73. Michelakis, E., Tymchak, W., Lien, D. et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension. Circulation 2002, 105: 2398-403.
74. Galie, N., Ghofrani, H.A., Torbicki, A. et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353: 2148-57.
75. Ghofrani, H.A., Rose, F., Schermuly R.T. et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003, 42: 158-64.
76. Sastray, B.K.S., Narasimhan, C., Reddy, N.K., Raju, B.S. Clinical efficacy of sildenafil in primary pulmonary hypertension. J Am Coll Cardiol 2004, 43: 1149-53.
77. Chockalingam, A., Gnanavelu, G., Venkatesan, S. et al. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int J Cardiol 2005, 99: 91-5.
78. Kataoka, M., Satoh, T., Anzai, T. et al. Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. Circ J 2005, 69: 461-5.
79. Ghofrani, H.A., Wiedemann, R, Rose, F. et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: A randomised controlled trial. Lancet 2002, 360: 895-900.
80. Aldashev, A.A., Kojonazarov, B.K., Amatov, T.A. et al. Phosphodiesterase type 5 and high-altitude pulmonary hypertension. Thorax 2005, 60: 683-7.
81. Richalet, J.P., Gratadour, P., Robach, P. et al. Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. Am J Respit Crit Care 2005, 171: 275-81.
82. Alaeddini, J., Uber, P.A., Park, M.H. et al. Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. Am J Cardiol 2004, 94: 1475-7.
83. Machado, R.F., Martyr, S., Kato, G.J. et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol 2005, 130: 445-53.
84. Stocker, C., Penny, D.J., Brizard, C.P. et al. Intravenous sildenafil and inhaled nitric oxide: A randomised trial in infants after cardiac surgery. Intensive Care Med 2003, 29: 1996-2003.
85. Ghofrani, H.A., Voswinckel R., Reichenberger, F. et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2004, 44: 1488-96.